RealTime Dynamix: Psoriasis EU (bi-annual)

The psoriasis market continues to grow, driven by the increasing treatment population and the continued uptake of biologics and advanced therapies. In particular, the alternative mechanism of action (MOA) agents have shown rapid growth, with the recent introductions of Almirall’s Ilumetri, Janssen’s Tremfya, and UCB’s Cimzia. Tracking the interplay of these treatments will be central to the 2019 report series, as well as assessing the impact of potential new market entrants, including AbbVie/Boehringer Ingelheim’s risankizumab, Eli Lilly’s mirikizumab, and UCB’s bimekizumab.

The RealTime Dynamix™: Psoriasis (EU) report series provides a detailed and timely look at current and future trends in the psoriasis market and the effects of the future shifting landscape. The bi-annual releases allow for close monitoring and trending of key performance metrics. In addition to the fixed trended measures, the report also includes variable content addressing key current issues updated bi-annually. The rapid field-to-insight turnaround time, highly relevant content, and unparalleled knowledge of the dermatology market make this an essential tool for companies competing in the space, as well as those with near-term plans to enter it.

The report is based on an online survey of ~250 dermatologists practicing in the EU5 (France, Italy, Germany, Spain, and the UK). Dermatologists meet screening criteria including time in practice, percent of professional time spent in clinical practice (vs. teaching or research), minimum number of psoriasis patients, and minimum number of psoriasis patients on biologic agents. Surveys are programmed in the local language.

Join Our Newsletter

This website intends to use cookies to improve the site and your experience. By continuing to browse the site you are agreeing to accept our use of cookies. If you require further information and/or do not wish to have cookies placed when using the site, visit About Cookies page.OKREAD MORE